Figure 2.

MFG-E8 deficiency enhances the early peritoneal inflammatory response to pristane. (a) Definition of peritoneal PMNs and macrophages subsets by flow cytometry, gating for CD11b⁺ F4/80⁺ macrophages, CD11b⁺ Ly6G⁺ PMNs in the peritoneum and representative images at 16 h, and on days 5, 10 and 14 after pristane treatment were shown. (b) Statistical analysis of total cells, CD11b⁺ cells, PMNs and macrophages at 0 h, 16 h, and days 5, 10 and 14 (n=8–12 mice per group). (c) Peritoneal cytokine profiles response to pristane. IL-12/IL-23p40, IL-6, TNF-α, IL-1β, TGF-β1 and IL-10 concentrations were determined by ELISA on days 5, 10 and 14 (n=8–12 mice per group). For all experiments, data are presented as means±S.E.M., *P<0.05, **P<0.01; ns, not significant. (d) Quantified peritoneal Ly6C⁺ monocytes from Mfge8^−/− mice and WT mice on day 14 with or without pristane injection by flow cytometry, and detected IFN-α levels on day 14 with ELISA. Data are presented as means±S.E.M., *P<0.05, **P<0.01 versus PBS treatment, ^#P<0.05 versus WT with pristane treatment